DAXOR CORP (10-Q) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside a cryobanking subsidiary. A significant portion of the company's financial profile is driven by a large investment portfolio of utility stocks and derivatives, which management utilizes to offset operating losses.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenues | $396,272 | $434,037 |
| Gross Profit | $204,495 | $281,569 |
| Operating Loss | $(1,342,156) | $(1,114,496) |
| Net Loss | $(92,419) | $(1,543,285) |
| Net Loss Per Share | $(0.02) | $(0.36) |
| Cash and Equivalents | $73,898 | $37,612 |
| Total Assets | $86,997,985 | $62,363,755 |
| Total Liabilities | $40,361,214 | $27,561,653 |
| Investment Portfolio (Fair Value) | $52,328,692 | $53,270,726 |
Investment Performance: The company reported significant "Other Income" of $1,833,829, primarily driven by realized gains on securities ($6.08M) and dividend income ($568k), partially offset by mark-to-market losses on short positions ($4.77M).
Material Changes vs. Prior Period
- Revenue Decline: Total operating revenues decreased 8.7% to $396,272. This was driven by an 11.9% drop in Blood Volume Kit sales (863 kits sold vs. 971 in Q1 2009) and a 10.3% decline in cryobanking services.
- Margin Compression: Gross profit margin on kit sales fell from 65.2% to 50.4% due to 4-10% price increases in production materials that were not passed to customers.
- Increased R&D Spend: Research and Development expenses rose 45.4% to $891,965, reflecting continued investment in the BVA-100 and new projects (GFR, Total Body Albumin Analysis).
- Improved Net Loss: Despite higher operating losses, the Net Loss improved significantly from $(1.54M) to $(92k) due to strong investment income.
- Liquidity: Cash and cash equivalents decreased from $277,088 to $73,898. However, the company maintains a substantial portfolio of available-for-sale securities.
Outlook, Risks, and Contingencies
- Investment Strategy: The company relies on its investment portfolio (primarily electric utilities) to fund operations. Management maintains a policy of capital preservation and generating income via dividends and option sales. Net short positions are limited to 15% of the portfolio value.
- Unrealized Losses: Significant unrealized losses exist in specific holdings, including Dynegy, Inc. ($993k loss) and Citigroup, Inc. ($627k loss). Management determined no impairment charge is necessary, citing the companies' improved liquidity and long-term value.
- Regulatory Risks:
- Reimbursement: CMS policy changes in 2008 eliminated separate Medicare reimbursement for diagnostic radiopharmaceuticals (Volumex), requiring hospitals to absorb costs. The impact on private insurers remains unclear.
- SEC Inquiry: The company received Wells Notices in 2005, 2007, and 2009 regarding potential violations of the Investment Company Act (operating as an unregistered investment company). No closing notice has been received, but the matter remains open.
- Customer Concentration: Four hospitals accounted for 56.65% of Blood Volume Kit sales in Q1 2010.
- Dividend: A dividend of $0.10 per share was declared on May 10, 2010.
Investor Verification Checklist
- Investment Dependency: Verify the sustainability of the investment portfolio as the primary offset to operating losses; the core medical business remains unprofitable.
- SEC Status: Monitor the status of the SEC Wells Notices regarding the Investment Company Act classification.
- Reimbursement Policy: Assess the impact of CMS reimbursement policies on hospital adoption of the BVA-100 and Volumex kits.
- Concentration Risk: Evaluate the risk associated with four customers representing over 56% of kit sales.
- Impairment Assessment: Review the rationale for not impairing Dynegy and Citigroup holdings despite significant unrealized losses (42% and 31% below cost, respectively).